CN1205975C - Chinese medicine for treating prostatitis - Google Patents
Chinese medicine for treating prostatitis Download PDFInfo
- Publication number
- CN1205975C CN1205975C CNB031019897A CN03101989A CN1205975C CN 1205975 C CN1205975 C CN 1205975C CN B031019897 A CNB031019897 A CN B031019897A CN 03101989 A CN03101989 A CN 03101989A CN 1205975 C CN1205975 C CN 1205975C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- prostatitis
- moschus
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 201000007094 prostatitis Diseases 0.000 title abstract description 69
- 150000001875 compounds Chemical class 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 34
- 241001250596 Pleione Species 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 241000972155 Moschus Species 0.000 claims 4
- 229940023488 pill Drugs 0.000 claims 2
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000766380 Iphigenia Species 0.000 abstract 1
- 241000865486 Knoxia Species 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 240000003152 Rhus chinensis Species 0.000 abstract 1
- 235000014220 Rhus chinensis Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 27
- 244000153234 Hibiscus abelmoschus Species 0.000 description 18
- 210000004907 gland Anatomy 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 208000013507 chronic prostatitis Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000002307 prostate Anatomy 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 210000004908 prostatic fluid Anatomy 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000762 glandular Effects 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 239000000787 lecithin Substances 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000005453 pelletization Methods 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010069918 Bacterial prostatitis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002640 perineum Anatomy 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005214 Poroma Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000001013 eccrine acrospiroma Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 210000005125 simple columnar epithelium Anatomy 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicine for treating prostatitis, particularly to a traditional Chinese medicine which is prepared from giant knotweed rhizome, sargentgloryvine stem, red sage root, indian iphigenia bulb, knoxia root, Chinese gall, musk, etc.
Description
Technical field
The present invention relates to a kind of Chinese medicine of resistance prostatitis, particularly the Chinese medicine made from Chinese crude drugs such as Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis, Moschus.
Background technology
Chronic prostatitis is a kind of common and multiple urology department illness, and according to statistics, male 30～40% suffers from chronic prostatitis (the Jiangsu traditional Chinese medical science 2000 in various degree more than 35 years old; (2): 43).The reason complexity of primary disease, symptom is various, and course of disease delay is obstinate difficult, treats more thornyly, has a strong impact on the adult male physical and mental health.Therefore, treat prostatitic medicine safely and effectively for one, patients with chronic prostatitis is needed just.
Whole nation patients with chronic prostatitis surpasses 100,000,000, and is very big the hold concurrently probability of syndrome of blood stasis of damp-heat accumulation to occur, therefore treats the medicine of the damp and hot double syndrome of blood stasis of chronic prostatitis, and vast market prospect is arranged.
In recent years, along with going deep into of clinical research, many scholars think, stasis of blood resistance, damp and hot and to suffer from a deficiency of the kidney be the main pathology of chronic prostatitis.We observe chronic prostatitis and mainly occur between twenty and fifty period in secular clinical practice, though part patient exists weak, dizzy, the symptom of sexual dysfunction etc. similar " suffering from a deficiency of the kidney ", but be not directly to be caused by chronic prostatitis, so we think damp and hot, blood stasis is the main pathological factor of chronic prostatitis, " damp and hot is disease, the turbid retardance of the stasis of blood " that scholars such as this understanding and Wang Qi propose is morbidity key identical of views of chronic prostatitis.So in treatment, answer clearing away heat-damp and promoting diuresis, promoting blood circulation and stopping pain.
Existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
The invention provides a kind of Chinese medicine preparation of resistance prostatitis, this Chinese medicine preparation is made with Chinese crude drugs such as Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis, Moschus.
According to theory of Chinese medical science, chronic prostatitis belongs to traditional Chinese medical science stranguria, smart turbid, white disease category such as excessive, mainly betide person between twenty and fifty,, experience damp and hot evil poison how because of ignoring the pudendum health, or lying on bed for a long time wetland, it is empty that impairment caused by overstrain excessively makes kidney qi lose, and damp and hot evil poison is gone into by lower orifices in an opponent's defence, contaminates in last, the retardance QI and blood, the stasis of blood and be trouble; Or insobriety, edible pungent, damp-heat accumulation is in body of gland, damp and hotly goes into network, and stagnation of QI-blood forms; Or the criminal's of mistake masturbation or sexual strain, or bear essence and do not let out, essence and blood stasis of blood dysentery Jiao feels damp and hot heresy again, thereby causes primary disease.Be main pathological characters with damp-heat accumulation, stagnation of QI-blood in a word.Damp-heat flowing down to the urinary bladder, then frequent micturition, urgent micturition, dysurea, urethra scorching hot; The damp-heat accumulation part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, mechanism of qi retardance and blood trouble causes the turbid retardance of the stasis of blood, stagnation of QI and blood may bring about pain then lacks abdomen, perineum weighs down pain or uncomfortable.Urethral orifice has a little mucus, and oliguria with yellow urine also is due to the damp invasion of lower energizer, and tongue is dark red or purple dark, tongue limit petechia ecchymosis, and yellowish fur or Huang, stringy and rolling pulse or string be puckery to be damp-heat accumulation the resembling of blood stasis of holding concurrently.With the passing of time damp-heat accumulation must the essence and blood stasis of blood stagnate, so prostate can have poroma, tenderness.So suitable clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, detoxicating and resolving stagnation of pathogens are gone up in treatment.Though prostate does not belong to the six internal organs of the traditional Chinese medical science, so similar (Wu Shaogang, clinical thinking of Wang Qi treatment CP of its excretory function to six internal organs.Shandong journal of Chinese medicine 1994,13 (10): 438),, note the product of the turbid tonneau of the row of selecting for use according to the principle of the traditional Chinese medical science " internal organs is a usefulness to lead to "; To impel the discharge of the long-pending thing of the prostate stasis of blood, be the key that improves clinical efficacy, prescription of the present invention is established just in view of the above.
Rhizoma Polygoni Cuspidati in the side, bitter cold is returned liver and gall, lung meridian, can clearing away heat-damp and promoting diuresis again can blood circulation promoting and blood stasis dispelling, detoxicating and resolving stagnation of pathogens, kind " controlling the five types of stranguria nebulousurine " (" the southern regions of the Yunnan Province book on Chinese herbal medicine ") is for the turbid key medicine of tonneau row, so think monarch; The Caulis Sargentodoxae bitter in the mouth is flat, returns large intestine, Liver Channel, function removing toxicity for eliminating carbuncles, clearing away heat-damp and promoting diuresis, promoting blood circulation and stopping pain; The Radix Salviae Miltiorrhizae bitter in the mouth, cold nature, GUIXIN bag, liver, warp are the key medicine of blood circulation promoting and blood stasis dispelling, still can nourishing blood to tranquillize the mind; The Pseudobulbus Cremastrae Seu Pleiones bitter in the mouth is cold in nature, the special detoxicating and resolving stagnation of pathogens of merit, clearing away heat and cooling blood, more than three flavors be altogether ministerial drug in the side.Assistant is with Radix Knoxiae removing fluid-retention by purgation, detoxicating and resolving stagnation of pathogens, the Galla Chinensis removing toxic substances and promoting subsidence of swelling, removing dampness is held back skin ulcer, the property of its astringent therapy can be prevented clear profit such as Rhizoma Polygoni Cuspidati, Radix Knoxiae too, more than two flavors be adjuvant drug in the side altogether.The Moschus blood circulation promoting and dispersing pathogen accumulation, reducing swelling and alleviating pain, the gas that can borrow its perfume (or spice) to scurry draw all medicines and goes into meridians again, so make for Fang Zhongzuo.More than all medicines assist mutually, play clearing away heat-damp and promoting diuresis altogether, blood circulation promoting and blood stasis dispelling, the effect of detoxicating and resolving stagnation of pathogens.In order to do the clear humidifying of heat, QI and blood is transferred smooth, and the long-pending thing of the prostate stasis of blood is discharged.Disease is expected more.
Chinese medicine preparation of the present invention has clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, detoxicating and resolving stagnation of pathogens effect.Cure mainly the chronic prostatitis damp-heat accumulation syndrome of blood stasis of holding concurrently.Disease is seen frequent micturition, urgent micturition, dysurea, urethra scorching hot, perineum, few abdomen weigh down pain or uncomfortable, urethral orifice often has a small amount of mucus, the heeltap not to the utmost, bitter taste, oliguria with yellow urine, tongue is dark red or purplish tongue is dark, tongue limit petechia ecchymosis, yellowish fur or Huang, stringy and hesitant pulse or stringy and rolling pulse.
Its prescription of Chinese medicine preparation of the present invention consists of:
Rhizoma Polygoni Cuspidati 375-1500 part Caulis Sargentodoxae 291-1166 part Radix Salviae Miltiorrhizae 291-1166 part
Pseudobulbus Cremastrae Seu Pleiones 250-1000 part Radix Knoxiae 133-534 part Galla Chinensis 208-834 part
Moschus 5-20 part
Preferably
Rhizoma Polygoni Cuspidati 562-1000 part Caulis Sargentodoxae 437-777 part Radix Salviae Miltiorrhizae 437-777 part
Pseudobulbus Cremastrae Seu Pleiones 375-666 part Radix Knoxiae 200-356 part Galla Chinensis 312-556 part
Moschus 7.5-13.3 part
More preferably
500 parts of 583 parts of Pseudobulbus Cremastrae Seu Pleioness of 583 parts of Radix Salviae Miltiorrhizaes of 750 portions of Caulis Sargentodoxae of Rhizoma Polygoni Cuspidati
10 parts in 417 parts of Moschus of 267 parts of Galla Chinensiss of Radix Knoxiae
In more than forming, weight is calculated with crude drug, if be unit with the gram, this composition can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, 1000 bags of granules, oral liquid 1000 peace bottles etc., also can make big packing as granule, as the 100-500 bag, specifically can be 100 bags, 125 bags, 200 bags, 250 bags, 500 bags etc., every bag can be used as taking dose 1 time.
More than form, as if being unit with the gram, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 125 bags, take the 1-2 bag at every turn, can take 62.5-125 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be a unit with milli part also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, and for especial patient, the proportioning of the amount of can corresponding adjustment forming increases or reduce being no more than 100%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention, can add the medicine acceptable carrier when being prepared into medicament, described medicine acceptable carrier can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc., preferably capsule.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Chinese medicine preparation of the present invention prepares by the following method.Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis with alcohol extraction after, use the acetone precipitation remove impurity, reclaim solution, obtain extract; With this extract and Moschus and the mixing of medicine acceptable carrier, make preparation.Specifically can be:
1. Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, the above Six-element medical material of gallic extraction and purification process 3100g, be ground into coarse granule, with 60% ethanol extraction three times, each 8 times of amounts, all extracted 1.0 hours, merge medicinal liquid, filter, in 65 ℃, decompression recycling ethanol under vacuum-0.07Mpa condition, be concentrated into relative density 1.17～1.20 (60 ℃), emit concentrated solution, constantly stir, when about 40 ℃ of concentrated solution, add the acetone of 4 times of amount concentrated solution volumes, standing over night, get supernatant at 65 ℃, reclaim under reduced pressure acetone under vacuum-0.07Mpa condition, and be concentrated into relative density 1.20～1.25 (60 ℃), add 50g microcrystalline Cellulose and 50g pregelatinized Starch and stir, in 55 ℃, dry under vacuum-0.09Mpa condition, shovel out dried cream, cross 60 eye mesh screen crushing and pelletizings, get extract particles.
2. the preparation technology of resistance prostatitis herbal mixture
Be taken into Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis extract 10g and 10g artificial Moschus mix homogeneously earlier, cross 40 mesh sieves 3 times, progressively mixed powder and all the other medicated powder equivalent increase progressively mixing again, cross 40 mesh sieves 3 times at every turn, press pharmaceutical dosage form and add adjuvant, make 1000 of capsules, 1000 in tablet, 500 bags of electuaries, 500 of oral liquids etc.
Below by effect experiment beneficial effect of the present invention is described.
Test used medicine for the medicine that the method according to the embodiment of the invention 1 prepares, be called the resistance prostatitis compound recipe, positive control uses the easypro ball in prostatitis, and experimental result is as follows.
The test of resistance prostatitis herbal mixture resistance prostatitis effect
Experiment material
One, medicine: the resistance prostatitis compound recipe, carry forward medical sci-tech development corporation, Ltd. by Changsha lot number 000906 is provided.The prostatitis ball that relaxes, the Kang Dini of Beijing pharmaceutical factory, lot number 001208.Aspirin, Hunan pharmaceutical factory produces, lot number 000624.Hydrochlorothiazide, Shi Qi pharmaceutical factory in Guangdong produces, lot number 000419.Hydrocortisone, people pharmaceutical factory of Tianjin aminoacid company produces, lot number 000603.FUFANG DANSHEN PIAN, White Cloud Mountain, Guangdong pharmaceutical factory of traditional Chinese medicine produces, lot number 010303-603.Ampicillin is produced 0.5mg/ bottle, lot number 001112 by Harbin Pharmaceutical Factory.Fluconazol, handsome restraint pharmaceutical factory, Henan produces 50mg/ sheet, lot number 20010221.
Two, animal: the SD rat, body weight 300-350g, ♂, is provided the quality certification number by 60 by Hunan College of Traditional Chinese Medicine's animal center: the moving word of doctor 20-001 number.The SD rat, body weight 180-220g, 120, ♀, ♂ half and half.Body weight 150-180g, ♂, 110.Provide the quality certification number by Hu'nan Inst. of Plarmaceutical Industry: 039.Kunming mouse, body weight 20-25g, 60, ♂.Body weight 18-22g, 50, ♀, ♂ half and half.Provide the quality certification number by Hu'nan Inst. of Plarmaceutical Industry: 040.
Experimental technique and result
One, the resistance prostatitis compound recipe is to the inhibitory action of rat bacterial prostatitis
1, to the influence of prostatitis rat lecithin density, total white blood cells and clump count: the SD rat, 300-350g, ♂, is divided into 6 groups at random by 60.(1) normal control group; (2) model group; (3) the easypro ball group (3.5g/kg) in prostatitis; (4)-(6) the basic, normal, high dosage group of resistance prostatitis compound recipe (1.8,3.6,7.2g/kg), ig, 10ml/kg, successive administration 7 days, after administration the 4th day, except that the normal control treated animal, all the other each treated animals are pressed the literature method modeling, and method is after abdomen is annotated pentobarbital sodium 45mg/kg anesthesia, at the aseptic condition median incision of lower abdomen, in the prostate abdominal part, injection 1.4 * 10
7CFU/ml escherichia coli normal saline suspension 0.1ml.Put into cage after the stitching and raise, animal continues administration after the modeling, and puts to death after administration in the 7th day, cuts open the belly rapidly, gets prostatic fluid and measures leukocyte count, checks lecithin density simultaneously, and the lecithin standards of grading are: full perimeter 4 minutes; 3/4 perimeter 3 minutes; 1/2 perimeter 2 minutes; 1 part of 1/4 perimeter.Get prostatic fluid enumeration of bacterial colonies number again.The resistance prostatitis compound recipe has the obvious suppression effect to the rat bacterial prostatitis as a result, can improve lecithin density in the prostate, reduces leukocyte count, suppresses colibacillary growth in the body of prostate.See Table 1.
Table 1 resistance prostatitis compound recipe is to prostatitis rat prostate lecithin density
And the influence of total white blood cells, clump count (n=10, X ± SD)
Group dosage lecithin leukocyte clump count
(g/kg) (integration) (10
9/ L) (10
6/ L)
Normal control group-3.4 ± 0.5 0.832 ± 0.199-
Model group-1.7 ± 0.7
*7.012 ± 3.023
*7.2 ± 6.1
Ball 3.5 2.9 ± 0.7 relaxes in the prostatitis
△ △4.460 ± 2.754 2.6 ± 4.0
Resistance prostatitis compound recipe 1.8 2.5 ± 0.8
△5.016 ± 2.169 3.1 ± 3.8
Resistance prostatitis compound recipe 3.6 3.0 ± 0.8
△ △4.237 ± 1.777
△1.8 ± 2.6 △
Resistance prostatitis compound recipe 7.2 3.4 ± 0.7
△ △3.980 ± 2.032
△.3 ± 0.9
△ △
Compare with matched group
*P＜0.01; Compare with model group
△P＜0.05,
△ △P＜0.01.
2, the resistance prostatitis compound recipe is to the histological influence of rat bacterial prostatitis [1-4]
Perusal: normal control group prostata tissue does not have hyperemia, edema, hemorrhage, adhesion etc., and prostatic fluid is more limpid.The hyperemia of model control group prostata tissue, edema are obvious, harder, and prostatic fluid is a purulence liquid.Relax and organize the prostata tissue mild hyperaemia in the prostatitis, no edema, and prostatic fluid is more limpid.Low, the middle dosage group of resistance prostatitis compound recipe prostate has hyperemia and edema in various degree, and prostatic fluid is extremely limpid by thickness.Resistance prostatitis compound recipe high dose group prostata tissue mild hyperaemia, no edema, prostatic fluid is more limpid.
Mirror is observed down: 1. normal control group: glandular epithelium is a simple columnar epithelium, the acinus out-of-shape, and glandular epithelium often protrudes the wrinkle wall to lumen of gland.Intracavity has is dyed pink secretions.Between the visible a small amount of connective tissue of matter, do not see cell infiltration, the blood capillary size is consistent.2. model control group: 7 routine glandular epithelium change, 2 routine epithelium degeneration necrosis.5 routine lumens of gland enlarge, and pus cell is in various degree arranged in the 9 routine lumens of gland, and blue purple engrain thing is wherein arranged in the 1 routine lumen of gland.Matter hyperemia between 1 example is visible, 1 routine blood vessel enlarges.Each example all has cell infiltration in various degree, the visible proliferation of fibrous tissue of 9 examples, and 1 routine fat becomes.3. resistance prostatitis compound recipe high dose: 7 routine bodies of gland recover normally substantially, and the flat sample of part epithelium changes.1 routine lumen of gland enlarges, and in the 3 routine lumens of gland a small amount of pus cell is arranged.Matter is normal between 6 examples, the visible slight hematoma of 2 examples, visible a small amount of cell infiltration in the matter between 4 examples, the visible fibroplasia of 3 examples.4. dosage in the resistance prostatitis compound recipe: between between low, the high dose, 5 routine bodies of gland recover normally substantially, and the flat sample of part epithelium changes.1 routine glandular epithelium degeneration necrosis.2 routine lumens of gland enlarge, and in the 4 routine lumens of gland a small amount of pus cell are arranged.Matter is normal between 5 examples, the visible slight hematoma of 2 examples, visible a small amount of cell infiltration in the matter between 4 examples, the visible fibroplasia of 5 examples.5. resistance prostatitis compound recipe low dosage: 3 routine bodies of gland recover normally substantially, and the flat sample of part epithelium changes 1 routine glandular epithelium degeneration necrosis.3 routine lumens of gland enlarge, and in the 5 routine lumens of gland a small amount of pus cell are arranged.Matter is normal between 3 examples, the visible slight hematoma of 2 examples, visible a small amount of cell infiltration in the matter between 7 examples, the visible fibroplasia of 6 examples.6. the prostatitis ball group of relaxing: 5 routine bodies of gland recover normally substantially, and the visible epithelium of 1 example changes, and flat or hypertrophy is multiple layer, 1 routine exuviation necrosis.5 routine lumens of gland enlarge, and are full of a small amount of pus cell in the 5 routine lumens of gland.The visible hematoma of matter between 2 examples, 5 examples have light to moderate cell infiltration and fibroplasia, the visible steatosis of matter between 1 example.
With essence intracavity cell infiltration, adenomatosis, lesion degrees such as a matter inflammation are divided into level Four (++ ++ ++ ++ ++), and lesion degree of each section of observed and recorded also carries out statistical procedures, the results are shown in Table 2.Matter cell infiltration between the resistance prostatitis compound recipe obviously suppresses to reach in the atrium, its action intensity is relevant with drug dose.
Table 2 resistance prostatitis compound recipe is to the scorching histological influence of rat prostate
(n＝10，X±SD)
Matter inflammation between glandular epithelium in the group dosage lumen of gland
(g/kg) inflammatory cell hypertrophy
Matched group----
Model group-2.5 ± 1.2 2.4 ± 1.1 2.7 ± 0.9
Ball 3.5 1.0 ± 1.2 relaxes in the prostatitis
*1.1 ± 1.3
*1.0 ± 1.2
*
Resistance prostatitis compound recipe 1.8 1.3 ± 1.4 1.5 ± 1.2 1.6 ± 1.3
*
Resistance prostatitis compound recipe 3.6 1.0 ± 1.5
*1.0 ± 1.2
*1.0 ± 1.2
*
Resistance prostatitis compound recipe 7.2 0.6 ± 1.1
*0.7 ± 0.9
*0.7 ± 0.9
*
Compare with model group
*P＜0.05,
*P＜0.01.
Two, antiinflammatory action
1. to the influence of mice ear:
Kunming mouse, 20～25g, ♂, is divided into 6 groups, (1) matched group at random by 60; (2) aspirin group (200mg/kg); (3) the easypro ball group (7.4g/kg) in prostatitis; (4)-(6) the basic, normal, high dosage group of resistance prostatitis compound recipe (3.9,7.8,15.6g/kg), ig, 20ml/kg, successive administration 7 days, once a day, after the last administration behind the 1h, every Mus auris dextra is coated with dimethylbenzene 0.1ml, behind the 15min, the cervical vertebra dislocation is put to death, and cuts ears, draw materials in the punching of left and right sides auricle same area with card punch, weigh respectively, with about the difference of two auricle weight as the swelling degree, and calculate suppression ratio.The results are shown in Table 3.The resistance prostatitis compound recipe (7.8,15.6g/kg) can obviously suppress mice auricle swelling, have antiphlogistic effect.
Table 3 resistance prostatitis compound recipe is to the influence of mice ear (n=10, X ± SD)
Group dosage swelling degree suppression ratio
(g/kg) (mg) (％)
Matched group--15.8 ± 5.5-
Aspirin 0.2 7.6 ± 3.6
*51.9
Ball 7.4 10.1 ± 4.9 relaxes in the prostatitis
*36.1
Resistance prostatitis compound recipe 3.9 15.1 ± 4.9 4.4
Resistance prostatitis compound recipe 7.8 9.1 ± 5.1
*42.4
Resistance prostatitis compound recipe 15.6 7.5 ± 2.5
*52.5
Compare with matched group
*P＜0.05,
*P＜0.01.
2, to the influence of pedal swelling due to the rat carrageenan
The SD rat, 50, male, be divided into 5 groups at random, (1) matched group; (2) the easypro ball group (3.5g/kg) in prostatitis; (3)-(5) the basic, normal, high dosage group of resistance prostatitis compound recipe (1.8,3.6,7.2g/kg), ig, 10ml/kg, be administered once every day, continuous 7 days, 1h after the last administration was in the right sufficient sole of the foot of rat bottom injection 1% chondrus ocellatus Holmes 0.1ml, cause scorching preceding normal foot sole of the foot volume and cause scorching back 1,2,4,6h mensuration swelling degree of the paw (causing scorching metapedes sole of the foot volume is the swelling degree with the difference that causes scorching front foot sole of the foot volume) with capillary tube amplifying method mensuration, check the significance of comparable group differences with t.The results are shown in Table 4, resistance prostatitis compound recipe, dosage are 3.6,7.2g/kg, and causing scorching back 1-4h can obviously suppress rat paw edema, has antiphlogistic effect.
The influence of foot swelling due to the table 4 resistance prostatitis compound recipe on Carrageenan (n=10, X ± SD)
Group dosage causes scorching front foot and causes scorching back swelling degree (ml)
(g/kg) volume (ml) 1h 2h 4h 6h
Matched group--1.08 ± 0.09 0.38 ± 0.13 0.56 ± 0.13 0.64 ± 0.13 0.59 ± 0.13
Ball 3.5 1.11 ± 0.10 0.25 ± 0.09 of relaxing, prostatitis
*0.40 ± 0.12
*0.53 ± 0.13 0.55 ± 0.09
Compound recipe 1.8 1.04 ± 0.11 0.35 ± 0.06 0.45 ± 0.11 0.57 ± 0.10 0.58 ± 0.12
Compound recipe 3.6 1.06 ± 0.13 0.27 ± 0.10
*0.37 ± 0.15
*0.50 ± 0.09
*0.53 ± 0.11
Compound recipe 7.2 1.09 ± 0.08 0.24 ± 0.09
*0.34 ± 0.11
*0.45 ± 0.13
*0.49 ± 0.12
Compare with matched group
*P＜0.05,
*P＜0.01.
3, to the bullate influence of rat granuloma
The SD rat, ♂, is divided into 6 groups, (1) matched group at random by 60; (2) hydrocortisone group (12.5mg/ml.2ml/kg.sc); (3) the easypro ball group (3.5g/kg) in prostatitis; (4)-(6) the basic, normal, high dosage group of resistance prostatitis compound recipe (1.8,3.6,7.2g/kg), experiment is preceding with the rat etherization, in the subcutaneous implantation one sterilization cotton balls (10 ± 1mg diameter 6.5-8.5mm) of left and right sides groin, each cotton balls adds each 0.1mg of penicillin and streptomycin in case infect, and begins administration after the stitching.Ig, 10ml/kg, successive administration 7 days, once a day, cotton balls is taken out in the execution that dislocates in the 8th day, rejects fatty tissue, dries 2h in 60 ℃ of baking boxs, weighs, and it is heavy to deduct cotton balls, is granuloma and weighs, comparable group differences, and calculating suppression ratio.The results are shown in Table 5.The resistance prostatitis compound recipe (3.6,7.2g/kg) can obviously suppress rat granuloma and swell, have antiphlogistic effect.
The bullate influence of table 5 pair rat granuloma (n=10, X ± SD)
Group dosage granuloma weight suppression ratio
(g/kg) (mg) (％)
Matched group--81.3 ± 19.4-
Hydrocortisone 25mg/kg, SC 47.4 ± 16.7
*41.7
Ball 3.5 65.6 ± 21.5 19.3 of relaxing, prostatitis
Resistance prostatitis compound recipe 1.8 67.3 ± 17.5 17.2
Resistance prostatitis compound recipe 3.6 65.0 ± 26.6 20.0
Resistance prostatitis compound recipe 7.2 53.1 ± 27.0
*34.7
Compare with matched group
*P＜0.05,
*P＜0.01.
The specific embodiment:
Further specify the present invention by the following examples
Embodiment 1:
The preparation of capsule agent
Prescription:
Rhizoma Polygoni Cuspidati 750g, Caulis Sargentodoxae 583g, Radix Salviae Miltiorrhizae 583g, Pseudobulbus cremastrae seu pleiones 500g, Radix Knoxiae 267g, Galla Chinensis 417g, Moschus 10g
Make 1000 of capsules
Method for making
Above Six-element medical material 3100g, be ground into coarse granule, with 60% ethanol extraction three times, each 8 times of amounts, all extracted 1.0 hours, merge medicinal liquid, filter, in 65 ℃, decompression recycling ethanol under vacuum-0.07Mpa condition, be concentrated into relative density 1.17～1.20 (60 ℃), emit concentrated solution, constantly stir, when about 40 ℃ of concentrated solution, add the acetone of 4 times of amount concentrated solution volumes, standing over night, get supernatant at 65 ℃, reclaim under reduced pressure acetone under vacuum-0.07Mpa condition, and be concentrated into relative density 1.20～1.25 (60 ℃), add 50g microcrystalline Cellulose and 50g pregelatinized Starch and stir, in 55 ℃, dry under vacuum-0.09Mpa condition, shovel out dried cream, cross 60 eye mesh screen crushing and pelletizings, get extract particles.
Get Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis extract granule 10g and 10g artificial Moschus mix homogeneously, cross 40 mesh sieves 3 times, progressively mixed powder and all the other medicated powder equivalent increase progressively mixing again, cross 40 mesh sieves 3 times at every turn, press pharmaceutical dosage form and add adjuvant, make 1000 of capsules,
Embodiment 2
The preparation of tablet
Prescription
Rhizoma Polygoni Cuspidati 750g, Caulis Sargentodoxae 583g, Radix Salviae Miltiorrhizae 583g, Pseudobulbus cremastrae seu pleiones 500g, Radix Knoxiae 267g, Galla Chinensis 417g, Moschus 10g
Make 1000 in tablet
Method for making
Above Six-element medical material 3100g, be ground into coarse granule, with 60% ethanol extraction three times, each 8 times of amounts, all extracted 1.0 hours, merge medicinal liquid, filter, in 65 ℃, decompression recycling ethanol under vacuum-0.07Mpa condition, be concentrated into relative density 1.17～1.20 (60 ℃), emit concentrated solution, constantly stir, when about 40 ℃ of concentrated solution, add the acetone of 4 times of amount concentrated solution volumes, standing over night, get supernatant at 65 ℃, reclaim under reduced pressure acetone under vacuum-0.07Mpa condition, and be concentrated into relative density 1.20～1.25 (60 ℃), add 50g microcrystalline Cellulose and 50g pregelatinized Starch and stir, in 55 ℃, dry under vacuum-0.09Mpa condition, shovel out dried cream, cross 60 eye mesh screen crushing and pelletizings, get extract particles.
Get Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis extract granule 10g and 10g artificial Moschus mix homogeneously, cross 40 mesh sieves 3 times, progressively mixed powder and all the other medicated powder equivalent increase progressively mixing again, cross 40 mesh sieves 3 times at every turn, press pharmaceutical dosage form and add adjuvant, make 1000 in tablet.
Embodiment 3
The preparation of electuary
Prescription
Rhizoma Polygoni Cuspidati 1500g, Caulis Sargentodoxae 1166g, Radix Salviae Miltiorrhizae 1166g, Pseudobulbus cremastrae seu pleiones 1000g, Radix Knoxiae 534g, Galla Chinensis 934g, Moschus 20g
Make 1000 bags
Method for making
Above Six-element medical material 6200g, be ground into coarse granule, with 60% ethanol extraction three times, each 8 times of amounts, all extracted 1.0 hours, merge medicinal liquid, filter, in 65 ℃, decompression recycling ethanol under vacuum-0.07Mpa condition, be concentrated into relative density 1.17～1.20 (60 ℃), emit concentrated solution, constantly stir, when about 40 ℃ of concentrated solution, add the acetone of 4 times of amount concentrated solution volumes, standing over night, get supernatant at 65 ℃, reclaim under reduced pressure acetone under vacuum-0.07Mpa condition, and be concentrated into relative density 1.20～1.25 (60 ℃), add 50g microcrystalline Cellulose and 50g pregelatinized Starch and stir, in 55 ℃, dry under vacuum-0.09Mpa condition, shovel out dried cream, cross 60 eye mesh screen crushing and pelletizings, get extract particles.
Get Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis extract 20g and 20g artificial Moschus mix homogeneously, cross 40 mesh sieves 3 times, progressively mixed powder and all the other medicated powder equivalent increase progressively mixing, each mistake 40 mesh sieves 3 times again, press pharmaceutical dosage form and add adjuvant, make 1000 bags of electuaries.
Embodiment 4
The preparation of oral liquid
Prescription
Rhizoma Polygoni Cuspidati 1500g, Caulis Sargentodoxae 1166g, Radix Salviae Miltiorrhizae 1166g, Pseudobulbus cremastrae seu pleiones 1000g, Radix Knoxiae 534g, Galla Chinensis 934g, Moschus 20g
Make 1000
Method for making
Medical material Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus cremastrae seu pleiones, Radix Knoxiae, the Galla Chinensis of recipe quantity are extracted, make with extra care the extract that obtains; Add suitable quantity of water, add Moschus and solubilizing agent again, heating for dissolving filters, and adds simple syrup, and sodium benzoate adds an amount of water again to 10000ml, and cold preservation is filtered, and is packaged in the 10ml peace bottle, with 100 ℃ of sterilization 30min, promptly.
Embodiment 5
The preparation of pill
Prescription
Rhizoma Polygoni Cuspidati 1500g, Caulis Sargentodoxae 1166g, Radix Salviae Miltiorrhizae 1166g, Pseudobulbus cremastrae seu pleiones 1000g, Radix Knoxiae 534g, Galla Chinensis 934g, Moschus 20g
Make 1000 bags
Method for making
Medical material Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus cremastrae seu pleiones, Radix Knoxiae, the Galla Chinensis of recipe quantity are extracted, make with extra care, and the extract that obtains adds Moschus, and general ball is after 60-80 ℃ of drying.Dried granule is carried out adorning 1000 bags after granulate handles, get final product.
Claims (7)
1, the prostatitic Chinese traditional compound medicine of a kind of treatment is characterized in that it is made by the Chinese medicine of following component,
Rhizoma Polygoni Cuspidati 375-1500 part Caulis Sargentodoxae 291-1166 part Radix Salviae Miltiorrhizae 291-1166 part
Pseudobulbus Cremastrae Seu Pleiones 250-1000 part Radix Knoxiae 133-534 part Galla Chinensis 208-834 part
Moschus 5-20 part.
According to the Chinese medicine preparation of claim 1, it is characterized in that 2, it is made by the Chinese medicine of following component,
Rhizoma Polygoni Cuspidati 562-1000 part Caulis Sargentodoxae 437-777 part Radix Salviae Miltiorrhizae 437-777 part
Pseudobulbus Cremastrae Seu Pleiones 375-666 part Radix Knoxiae 200-356 part Galla Chinensis 312-556 part
Moschus 7.5-13.3 part.
According to the Chinese medicine preparation of claim 1, it is characterized in that 3, it is made by the Chinese medicine of following component,
500 parts of 583 parts of Pseudobulbus Cremastrae Seu Pleioness of 583 parts of Radix Salviae Miltiorrhizaes of 750 portions of Caulis Sargentodoxae of Rhizoma Polygoni Cuspidati
10 parts in 417 parts of Moschus of 267 parts of Galla Chinensiss of Radix Knoxiae.
4, according to any one Chinese medicine preparation of claim 1-3, it is characterized in that described preparation is tablet, capsule, oral liquid, buccal tablet, granule, electuary, pill, powder, suspensoid, powder, solution, drop or drop pill.
According to the Chinese medicine preparation of claim 4, it is characterized in that 5, described preparation is a capsule.
6. the Chinese medicine preparation of claim 1 prevents and/or treats application in the prostatitic medicine in preparation.
7, according to the preparation method of the Chinese medicine preparation of claim 1, it is characterized in that, through following steps, Rhizoma Polygoni Cuspidati, Caulis Sargentodoxae, Radix Salviae Miltiorrhizae, Pseudobulbus Cremastrae Seu Pleiones, Radix Knoxiae, Galla Chinensis with alcohol extraction after, use the acetone precipitation remove impurity, recovery solution obtains extract; With this extract and Moschus and the mixing of medicine acceptable carrier, make preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031019897A CN1205975C (en) | 2003-01-30 | 2003-01-30 | Chinese medicine for treating prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031019897A CN1205975C (en) | 2003-01-30 | 2003-01-30 | Chinese medicine for treating prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429615A CN1429615A (en) | 2003-07-16 |
| CN1205975C true CN1205975C (en) | 2005-06-15 |
Family
ID=4789969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031019897A Expired - Lifetime CN1205975C (en) | 2003-01-30 | 2003-01-30 | Chinese medicine for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1205975C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727752A (en) * | 2012-06-19 | 2012-10-17 | 卞毓平 | Application of Wu Hu Dan capsules in preparing medicine used for treating gout |
| CN105232762A (en) * | 2015-10-10 | 2016-01-13 | 柳州草子吉生物科技有限公司 | Prostatitis and prostatic hyperplasia treatment traditional Chinese medicine composition and preparation method thereof |
-
2003
- 2003-01-30 CN CNB031019897A patent/CN1205975C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1429615A (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1879857A (en) | Medicinal powder for treating mammary gland disease | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1150041A (en) | Chinese patent medicine for curing gallstones and kidney stones | |
| CN1205975C (en) | Chinese medicine for treating prostatitis | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1823910A (en) | Joint pain preparation and its new preparation method | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1879701A (en) | Cold-treating medicine and preparation method thereof | |
| CN1191849C (en) | Chinese medicine for treating breast disease | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1823980A (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1824109A (en) | Liaoyuanqili medicinal preparation and its new preparation method | |
| CN1634407A (en) | Chinese traditional medicine preparation for treating cholecystitis | |
| CN107753800A (en) | A kind of Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN1265810C (en) | A pharmaceutical composition for treating cyclomastopathy, and its preparation method | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1254264C (en) | Chinese traditional medicine for treating rheumatoid arthritis, and preparing technique | |
| CN1840152A (en) | Health-caring capsule for middle- and old- aged man and preparation method thereof | |
| CN1544077A (en) | Chinese traditional medicine for treating chronic pharyngitis and its preparation | |
| CN1775268A (en) | Kidney-tonifying preparation and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG MADDISON PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TUO YUANBIN Effective date: 20070112 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070112 Address after: 163316 No. 241 hi tech Industrial Development Zone, Heilongjiang, Daqing Patentee after: HEILONGJIANG MAIDISEN PHARMACEUTICAL Co.,Ltd. Address before: 410007 Changsha Yuhua District of Hunan province orchard area successful court No. 151 Patentee before: Tuo Yuanbin |
|
| ASS | Succession or assignment of patent right |
Owner name: DAQING HUAKE CO., LTD. Free format text: FORMER OWNER: HEILONGJIANG MADISON PHARMACEUTICAL CO., LTD. Effective date: 20100528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 163316 NO.241, NEW+HIGH TECHNOLOGY INDUSTRY DEVELOPMENT ZONE,DAQING CITY, HEILONGJIANG PROVINCE TO: 163000 NO.241, JIANSHE ROAD, NEW+HIGH-TECH ZONE, DAQING CITY,HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100528 Address after: 163000 No. 241, Daqing hi tech Development Zone, Heilongjiang, Jianshe Road Patentee after: DAQING HUAKE Co.,Ltd. Address before: 163316 No. 241 hi tech Industrial Development Zone, Heilongjiang, Daqing Patentee before: HEILONGJIANG MAIDISEN PHARMACEUTICAL Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING HAIYAN PHARMACEUTICAL INDUSTRY CO., LTD., Free format text: FORMER OWNER: DAQING HUAKE CO., LTD. Effective date: 20140108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 163000 DAQING, HEILONGJIANG PROVINCE TO: 102200 CHANGPING, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140108 Address after: 102200 No. 16, life Garden Road, Beijing, Changping District Patentee after: YANGTZE RIVER PHARMACEUTICAL GROUP, BEIJING HAIYAN PHARMACEUTICAL CO.,LTD. Address before: 163000 No. 241, Daqing hi tech Development Zone, Heilongjiang, Jianshe Road Patentee before: DAQING HUAKE Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050615 |
|
| CX01 | Expiry of patent term | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: He Yan Document name: Notice of termination of patent right |